When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Akero Therapeutics (AKRO) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steatohepatitis [NASH].
AKRO has demonstrated very promising trial results for its lead candidate and the IPO funds will likely last the firm through 2022.
Company & Technology
San Francisco, California-based Akero was founded in 2017 to develop a therapy for the treatment of NASH, a serious type of